Reports Q1 revenue EUR 246.6M, consensus EUR 269.64M. Reports Q1 Yorvipath revenue EUR 197M. Reports Q1 Skytrofa revenue EUR 44M. “The FDA approval of YUVIWEL, our third consecutive TransCon product, and the robust patient uptake for YORVIPATH are cementing our position as a leading global biopharma,” said CEO Jan Mikkelsen.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma Swings to €629 Million Q1 2026 Profit on Strong Revenue Growth
- Ascendis Pharma Q1 2026 Results Highlight YORVIPATH Growth and U.S. Launch of YUVIWEL
- Ascendis Pharma Calls Full Redemption of $575 Million 2028 Convertible Notes After Share Price Surge
- Ascendis Pharma Updates ISIN for Nasdaq-Listed Ordinary Shares
- Ascendis Pharma Completes ADS-to-Ordinary Share Conversion and Begins Direct Nasdaq Trading